4.5.2 Centrally acting appetite suppressants

Sibutramine (dexfenfluramine and fenfluramine) has been withdrawn because the benefits of treatment does not outweigh the risk of serious adverse effects.

21st January 2010: The European Medicines Agency (EMA) has completed a review of the obesity medicine sibutramine (Reductil®) and has found that the cardiovascular risks of sibutramine outweigh its benefits. The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended suspension of the marketing authorisation for this medicine across the European Union.

Further information is available on the Link opens in new windowMHRA and Link opens in new windowEMA websites.

Previous: Anti-obesity drugs acting on the GI tract | Top | Next: Drugs used in nausea and vertigo